Schwartz Jeffrey Lawrence 4
4 · SpringWorks Therapeutics, Inc. · Filed Sep 16, 2019
Insider Transaction Report
Form 4
Schwartz Jeffrey Lawrence
Director10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2019-09-12+29,983→ 29,983 totalExercise: $18.00Exp: 2029-09-12→ Common Stock (29,983 underlying) - Award
Series A Convertible Preferred Stock
2019-03-29+40,000,000→ 6,078,103 total(indirect: See footnote)→ Common Stock (6,078,103 underlying) - Award
Series B Convertible Preferred Stock
2019-03-29+6,931,142→ 1,053,204 total(indirect: See footnote)→ Common Stock (1,053,204 underlying)
Footnotes (4)
- [F1]This option shall vest in equal monthly installments over the period of thirty six (36) months following September 12, 2019, subject to continued service to the Issuer on each vesting date.
- [F2]On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, BC SW, L.P. received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.
- [F3]On March 29, 2019, BC SW, L.P. acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer for $1.4428 per share. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.
- [F4]Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.